{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:09:30Z","timestamp":1793297370994,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yale New Haven Medical Staff Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the context of the fourth wave of the opioid overdose crisis, defined by fentanyl and stimulant co-use, we aimed to explore if there might be a relationship between exposure to xylazine in the fentanyl supply and patterns of crack\/cocaine use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This mixed methods study used data from four Connecticut-based sources: (1) the Office of the Chief Medical Examiner for fatal overdoses, 2019\u20132023, (2) community-based drug checking data, 2023\u20132024, (3) a structured survey of people who use drugs, 2024, and (4) one-on-one in-depth interviews, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Xylazine was detected in 19.2% of overdose fatalities involving fentanyl or a fentanyl analog (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095,849). Those with xylazine detected had a higher proportion of cocaine simultaneously detected, though this was not statistically significant (54.0% vs. 51.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.085). Cocaine detection rose over time in the fatality data, regardless of xylazine detection. There were 1,048 drug samples submitted to harm reduction organizations for drug checking. Using Fourier Transform Infrared Spectroscopy, 573 of the samples submitted tested positive for fentanyl or a fentanyl analog; 45.2% of these also tested positive for xylazine. Of 1048 samples, 276 tested positive for cocaine. Among the survey sample (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200988), 62.5% of participants self-reported xylazine exposure. Those who reported lifetime xylazine exposure also reported higher past-year crack\/cocaine use, though this was not statistically significant (89.1% vs. 81.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.336). Among our interview sample (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931), three themes emerged: (1) participants felt there was an inevitability of polysubstance use due to an increasingly volatile drug supply, (2) participants increased their crack\/cocaine use in response to perceived exposure to xylazine in their fentanyl supply, and (3) participants\u2019 drug patterning changed due to xylazine\u2019s presence (e.g., timing, drug sequencing, etc.). Two meta-inferences were identified: (1) overdose fatality data likely underestimate the \u201ctrue\u201d prevalence of xylazine in the street supply, and (2) people who use drugs are using crack\/cocaine in response to xylazine in their local fentanyl supply.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Xylazine exposure has likely contributed to an adaptive and increasing use of crack\/cocaine among people who use drugs in Connecticut. It is imperative that practitioners and policymakers are prepared to manage this triad of opioid-stimulant-sedative polysubstance use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01459-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:25:37Z","timestamp":1777692337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Crack\/cocaine use to manage xylazine exposure in fentanyl in Connecticut: findings from a convergent mixed methods study"],"prefix":"10.1186","volume":"23","author":[{"given":"Katherine","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma T.","family":"Biegacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Bogut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Znamierowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"River","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corona","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauretta E.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna L.","family":"Butner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Sue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"32","key":"1459_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.15585\/mmwr.mm7432a1","volume":"74","author":"LJ Tanz","year":"2025","unstructured":"Tanz LJ, Miller KD, Dinwiddie AT, Gladden RM, Asher A, Baldwin G, et al. Drug overdose deaths involving stimulants \u2015 United States, January 2018\u2013June 2024. MMWR Morb Mortal Wkly Rep. 2025;74(32):491\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm7432a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7410a3","author":"EW Lundstrom","year":"2025","unstructured":"Lundstrom EW. Synthetic opioid and stimulant co-involved overdose deaths by occupation and industry \u2014 United States, 2022. MMWR Morb Mortal Wkly Rep. 2025. https:\/\/doi.org\/10.15585\/mmwr.mm7410a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"1459_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350. https:\/\/doi.org\/10.1097\/YCO.0000000000000717.","journal-title":"Curr Opin Psychiatry"},{"issue":"20","key":"1459_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192013542","volume":"19","author":"S Font-Mayolas","year":"2022","unstructured":"Font-Mayolas S, Calvo F. Polydrug definition and assessment: the state of the art. IJERPH. 2022;19(20):13542. https:\/\/doi.org\/10.3390\/ijerph192013542.","journal-title":"IJERPH"},{"issue":"12","key":"1459_CR5","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1007\/s11606-022-07424-5","volume":"37","author":"RD Shearer","year":"2022","unstructured":"Shearer RD, Bart G, Reznikoff C. Rethinking the use of \u201cpolysubstance\u201d to describe complex substance use patterns. J Gen Intern Med. 2022;37(12):3174\u20135. https:\/\/doi.org\/10.1007\/s11606-022-07424-5.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"1459_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2023.2248360","volume":"50","author":"AM Bunting","year":"2024","unstructured":"Bunting AM, Shearer R, Linden-Carmichael AN, Williams AR, Comer SD, Cerd\u00e1 M, et al. Are you thinking what I\u2019m thinking? Defining what we mean by \u201cpolysubstance use.\u201d Am J Drug Alcohol Abuse. 2024;50(1):1\u20137. https:\/\/doi.org\/10.1080\/00952990.2023.2248360.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"1459_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2105\/AJPH.2025.308070","volume":"115","author":"KY Xu","year":"2025","unstructured":"Xu KY, Lin L, Grucza RA. Polysubstance use is not synonymous with poly substance use disorder. Am J Public Health. 2025;115(5):646\u20138. https:\/\/doi.org\/10.2105\/AJPH.2025.308070.","journal-title":"Am J Public Health"},{"key":"1459_CR8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7348a2","author":"LJ Tanz","year":"2024","unstructured":"Tanz LJ. Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths \u2014 United States, 2021\u20132024. MMWR Morb Mortal Wkly Rep. 2024. https:\/\/doi.org\/10.15585\/mmwr.mm7348a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40736","author":"J Pergolizzi Jr","year":"2023","unstructured":"Pergolizzi J Jr, Raffa R, LeQuang JAK, Breve F, Varrassi G. Old drugs and new challenges: a narrative review of nitazenes. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.40736.","journal-title":"Cureus"},{"issue":"34","key":"1459_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","volume":"68","author":"RM Gladden","year":"2019","unstructured":"Gladden RM, O\u2019Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine \u2014 25 states, July\u2013December 2017 to January\u2013June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(34):737\u201344. https:\/\/doi.org\/10.15585\/mmwr.mm6834a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102934","volume":"85","author":"PK Valente","year":"2020","unstructured":"Valente PK, Bazzi AR, Childs E, Salhaney P, Earlywine J, Olson J, et al. Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast. Int J Drug Policy. 2020;85:102934. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102934.","journal-title":"Int J Drug Policy"},{"issue":"26","key":"1459_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","volume":"72","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl\u2013involved overdose deaths with detected Xylazine \u2014 United States, January 2019\u2013June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7226a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR13","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7415a2","author":"S Huo","year":"2025","unstructured":"Huo S. Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients \u2014 Philadelphia, Pennsylvania, September 2024\u2013January 2025. MMWR Morb Mortal Wkly Rep. 2025. https:\/\/doi.org\/10.15585\/mmwr.mm7415a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"1459_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jat\/bkac049","volume":"46","author":"SL Kacinko","year":"2022","unstructured":"Kacinko SL, Mohr ALA, Logan BK, Barbieri EJ. Xylazine: pharmacology review and prevalence and drug combinations in forensic toxicology casework. J Anal Toxicol. 2022;46(8):911\u20137. https:\/\/doi.org\/10.1093\/jat\/bkac049.","journal-title":"J Anal Toxicol"},{"issue":"8","key":"1459_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136. https:\/\/doi.org\/10.2105\/AJPH.2022.306881.","journal-title":"Am J Public Health"},{"issue":"1","key":"1459_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0165-5728(00)00370-2","volume":"113","author":"V \u0106upi\u0107","year":"2001","unstructured":"\u0106upi\u0107 V, \u010coli\u0107 M, Pavi\u010di\u0107 L, Vu\u010devi\u0107 D, Varagi\u0107 VM. Immunomodulatory effect of xylazine, an \u03b12 adrenergic agonist, on rat spleen cells in culture. J Neuroimmunol. 2001;113(1):19\u201329. https:\/\/doi.org\/10.1016\/S0165-5728(00)00370-2.","journal-title":"J Neuroimmunol"},{"issue":"773","key":"1459_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/pgmj.66.773.244","volume":"66","author":"A Samanta","year":"1990","unstructured":"Samanta A, Roffe C, Woods KL. Accidental self administration of xylazine in a veterinary nurse. Postgrad Med J. 1990;66(773):244\u20135. https:\/\/doi.org\/10.1136\/pgmj.66.773.244.","journal-title":"Postgrad Med J"},{"key":"1459_CR18","doi-asserted-by":"crossref","unstructured":"T.Kumaravadivel D, Ganapathy GK, Mugunthan M. S. accidental self-injection of xylazine during work: A rare case [Internet]. 2018 Jul. Available from: https:\/\/www.researchgate.net\/publication\/326129001_ACCIDENTAL_SELF-INJECTION_OF_XYLAZINE_DURING_WORK_A_RARE_CASE","DOI":"10.51200\/bjms.v12i2.946"},{"issue":"6","key":"1459_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00006565-200112000-00012","volume":"17","author":"AJ Capraro","year":"2001","unstructured":"Capraro AJ, Wiley JF, Tucker JR. Severe intoxication from xylazine inhalation. Pediatr Emerg Care. 2001;17(6):447\u20138. https:\/\/doi.org\/10.1097\/00006565-200112000-00012.","journal-title":"Pediatr Emerg Care"},{"issue":"8","key":"1459_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/15563650.2022.2063135","volume":"60","author":"NS Ball","year":"2022","unstructured":"Ball NS, Knable BM, Relich TA, Smathers AN, Gionfriddo MR, Nemecek BD, et al. Xylazine poisoning: a systematic review. Clin Toxicol Phila. 2022;60(8):892\u2013901. https:\/\/doi.org\/10.1080\/15563650.2022.2063135.","journal-title":"Clin Toxicol Phila"},{"key":"1459_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36864","author":"S Ayub","year":"2023","unstructured":"Ayub S, Parnia S, Poddar K, Bachu AK, Sullivan A, Khan AM, et al. Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.36864.","journal-title":"Cureus"},{"issue":"7","key":"1459_CR22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","volume":"240","author":"S Choi","year":"2023","unstructured":"Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacol Berl. 2023;240(7):1561\u201371. https:\/\/doi.org\/10.1007\/s00213-023-06390-y.","journal-title":"Psychopharmacol Berl"},{"issue":"3","key":"1459_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15563650.2022.2159427","volume":"61","author":"JS Love","year":"2023","unstructured":"Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, et al. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol Phila. 2023;61(3):173\u201380. https:\/\/doi.org\/10.1080\/15563650.2022.2159427.","journal-title":"Clin Toxicol Phila"},{"issue":"1","key":"1459_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141. https:\/\/doi.org\/10.1186\/s12954-023-00879-7.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1459_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01052-4","volume":"21","author":"K Hill","year":"2024","unstructured":"Hill K, Minahan-Rowley R, Biegacki ET, Heimer R, Sue KL. Providers\u2019 knowledge and perception of xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study. Harm Reduct J. 2024;21(1):148. https:\/\/doi.org\/10.1186\/s12954-024-01052-4.","journal-title":"Harm Reduct J"},{"key":"1459_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001198","author":"A Dowton","year":"2023","unstructured":"Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, et al. Recognition and treatment of wounds in persons using xylazine: a case report from New Haven, Connecticut. J Addict Med. 2023. https:\/\/doi.org\/10.1097\/ADM.0000000000001198.","journal-title":"J Addict Med"},{"key":"1459_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/add.16388","author":"KL Sue","year":"2023","unstructured":"Sue KL, Hawk K. Clinical considerations for the management of xylazine overdoses and xylazine\u2010related wounds. Addict. 2023. https:\/\/doi.org\/10.1111\/add.16388.","journal-title":"Addict"},{"key":"1459_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107671","volume":"205","author":"TG Rhee","year":"2019","unstructured":"Rhee TG, Ross JS, Rosenheck RA, Grau LE, Fiellin DA, Becker WC. Accidental drug overdose deaths in Connecticut, 2012\u20132018: the rise of polysubstance detection? Drug Alcohol Depend. 2019;205:107671. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107671.","journal-title":"Drug Alcohol Depend"},{"key":"1459_CR29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.15585\/mmwr.mm7037a5","volume":"70","author":"S Thangada","year":"2021","unstructured":"Thangada S, Clinton H, Ali S. Notes from the field: xylazine, a veterinary tranquilizer, identified as an emerging novel substance in drug overdose deaths \u2014 Connecticut, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70:1303\u20134. https:\/\/doi.org\/10.15585\/mmwr.mm7037a5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR30","unstructured":"CT DPH. Unintentional drug overdose deaths in connecticut: a fact sheet \u2013 2020 update [Internet]. 2020 Mar. Report. Available from: https:\/\/portal.ct.gov\/-\/media\/dph\/injury-and-violence-prevention\/opioid-overdose-data\/fact-sheets\/fact-sheet-unintentional-drug-overdose-deaths_2019_4_24_2020.pdf?rev=8a4730cfd4604979b45cadff4ea74006&hash=594CAB41788CBFCB1E86E281C8C45331"},{"issue":"1","key":"1459_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/PAF.0000000000000622","volume":"42","author":"J Nunez","year":"2021","unstructured":"Nunez J, DeJoseph ME, Gill JR. Xylazine, a veterinary tranquilizer, detected in 42 accidental Fentanyl intoxication deaths. Am J Forensic Med Pathol. 2021;42(1):9\u201311. https:\/\/doi.org\/10.1097\/PAF.0000000000000622.","journal-title":"Am J Forensic Med Pathol"},{"key":"1459_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2025.2549499","author":"K Hill","year":"2025","unstructured":"Hill K, Heimer R, Sue KL. \u201cEverybody\u2019s liking it\u201d\u2014intentional use of Xylazine in Fentanyl among people who use drugs. Subst Use Misuse. 2025. https:\/\/doi.org\/10.1080\/10826084.2025.2549499.","journal-title":"Subst Use Misuse"},{"issue":"9","key":"1459_CR33","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1360-0443.2004.00694.x","volume":"99","author":"RN Bluthenthal","year":"2004","unstructured":"Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer R. Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. Addict. 2004;99(9):1136\u201346. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00694.x.","journal-title":"Addict"},{"issue":"3","key":"1459_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s10461-013-0572-3","volume":"18","author":"R Heimer","year":"2014","unstructured":"Heimer R, Barbour R, Palacios WR, Nichols LG, Grau LE. Associations between injection risk and community disadvantage among suburban injection drug users in Southwestern Connecticut, USA. AIDS Behav. 2014;18(3):452\u201363. https:\/\/doi.org\/10.1007\/s10461-013-0572-3.","journal-title":"AIDS Behav"},{"key":"1459_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102661","volume":"77","author":"TC Green","year":"2020","unstructured":"Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of Fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102661.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1459_CR36","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1111\/dar.70037","volume":"44","author":"M Ujeneza","year":"2025","unstructured":"Ujeneza M, Tardif J, Thompson E, Badea A, Morales A, Altomare\u2010Jarczyk C, et al. Point\u2010of\u2010care drug\u2010checking: assessing the Rhode Island drug supply using FTIR spectroscopy to detect Fentanyl, Xylazine and other substances. Drug Alcohol Rev. 2025;44(7):1866\u201374. https:\/\/doi.org\/10.1111\/dar.70037.","journal-title":"Drug Alcohol Rev"},{"issue":"Supplement 6","key":"1459_CR37","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1097\/PHH.0000000000001581","volume":"28","author":"TC Green","year":"2022","unstructured":"Green TC, Olson R, Jarczyk C, Erowid E, Erowid F, Thyssen S, et al. Implementation and uptake of the Massachusetts drug supply data stream: a statewide public health-public safety partnership drug checking program. J Public Health Manag Pract. 2022;28(Supplement 6):S347\u201354. https:\/\/doi.org\/10.1097\/PHH.0000000000001581.","journal-title":"J Public Health Manag Pract"},{"key":"1459_CR38","doi-asserted-by":"publisher","unstructured":"Uljon S. Advances in fentanyl testing. In: Advances in clinical chemistry [Internet]. Elsevier; 2023 [cited 2025 Aug 21]. p. 1\u201330. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242323000495https:\/\/doi.org\/10.1016\/bs.acc.2023.05.004","DOI":"10.1016\/bs.acc.2023.05.004"},{"key":"1459_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104102","volume":"118","author":"C Norman","year":"2023","unstructured":"Norman C, Marland V, McKenzie C, M\u00e9nard H, Nic Da\u00e9id N. Evaluation of Fentanyl immunoassay test strips for rapid in-situ detection of Fentanyl and Fentanyl analogs in seized samples and alternative matrices. Int J Drug Policy. 2023;118:104102. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104102.","journal-title":"Int J Drug Policy"},{"key":"1459_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104118","volume":"118","author":"AB Collins","year":"2023","unstructured":"Collins AB, Wightman RS, Macon EC, Guan Y, Shihipar A, Krieger M, et al. Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island. Int J Drug Policy. 2023;118:104118. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104118.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1459_CR41","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907. https:\/\/doi.org\/10.1007\/s11135-017-0574-8.","journal-title":"Qual Quant"},{"issue":"2","key":"1459_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"6pt2","key":"1459_CR43","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs\u2014Principles and practices. Health Serv Res. 2013;48(6pt2):2134\u201356. https:\/\/doi.org\/10.1111\/1475-6773.12117.","journal-title":"Health Serv Res"},{"issue":"1","key":"1459_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-025-02475-8","volume":"25","author":"A Younas","year":"2025","unstructured":"Younas A, F\u00e0bregues S, Munce S, Creswell JW. Framework for types of metainferences in mixed methods research. BMC Med Res Methodol. 2025;25(1):18. https:\/\/doi.org\/10.1186\/s12874-025-02475-8.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"1459_CR45","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/bmjqs-2023-016112","volume":"33","author":"TC Guetterman","year":"2024","unstructured":"Guetterman TC, Manojlovich M. Grand rounds in methodology: designing for integration in mixed methods research. BMJ Qual Saf. 2024;33(7):470\u20138. https:\/\/doi.org\/10.1136\/bmjqs-2023-016112.","journal-title":"BMJ Qual Saf"},{"key":"1459_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109003","volume":"227","author":"AH Kral","year":"2021","unstructured":"Kral AH, Lambdin BH, Browne EN, Wenger LD, Bluthenthal RN, Zibbell JE, et al. Transition from injecting opioids to smoking fentanyl in San Francisco, California. Drug Alcohol Depend. 2021;227:109003. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109003.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1459_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.15585\/mmwr.mm7306a2","volume":"73","author":"LJ Tanz","year":"2024","unstructured":"Tanz LJ, Gladden RM, Dinwiddie AT, Miller KD, Broz D, Spector E, et al. Routes of drug use among drug overdose deaths \u2014 United States, 2020\u20132022. MMWR Morb Mortal Wkly Rep. 2024;73(6):124\u201330. https:\/\/doi.org\/10.15585\/mmwr.mm7306a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR48","unstructured":"National harm reduction coalition. What is overamping? [Internet]. 2024 [cited 2025 Sep 11]. Available from: https:\/\/harmreduction.org\/issues\/overdose-prevention\/overview\/stimulant-overamping-basics\/what-is-overamping\/"},{"issue":"1","key":"1459_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01275-z","volume":"22","author":"MK Reed","year":"2025","unstructured":"Reed MK, Martin Gonz\u00e1lez K, Green TC, Esteves Camacho T, Laurano R, Clark-Garc\u00eda F, et al. \u201cAnything can happen\u201d: experiences of people using opioids in a xylazine market. Harm Reduct J. 2025;22(1):134. https:\/\/doi.org\/10.1186\/s12954-025-01275-z.","journal-title":"Harm Reduct J"},{"issue":"2","key":"1459_CR50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/ADM.0000000000001264","volume":"18","author":"M Tan","year":"2024","unstructured":"Tan M, Nassau T, Kuncio D, Higgins D, Teixeira Da Silva D, Tomlinson D, et al. Xylazine use among people who inject drugs, Philadelphia 2022. J Addict Med. 2024;18(2):194\u2013200. https:\/\/doi.org\/10.1097\/ADM.0000000000001264.","journal-title":"J Addict Med"},{"issue":"26","key":"1459_CR51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.15585\/mmwr.mm7326a2","volume":"73","author":"X Jiang","year":"2024","unstructured":"Jiang X, Connolly S, Strahan AE, Rivera Blanco L, Mikosz CA, Guy GP, et al. Reported xylazine use among adults aged \u226518 years evaluated for substance use treatment \u2014 United States, July 2022\u2013September 2023. MMWR Morb Mortal Wkly Rep. 2024;73(26):594\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm7326a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1459_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2025.100403","volume":"18","author":"JE Rudolph","year":"2026","unstructured":"Rudolph JE, Martinez-Ocasio LM, Feder KA, Tomko C, Cepeda JA, Kirk GD, et al. Characterizing patterns of opioid and stimulant use by route and associations with non-fatal overdose and xylazine use in people who have injected drugs from Baltimore, MD, 2023\u20132024. Drug Alcohol Depend Rep. 2026;18:100403. https:\/\/doi.org\/10.1016\/j.dadr.2025.100403.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"1459_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/10826084.2025.2549501","volume":"61","author":"PJA Kelly","year":"2026","unstructured":"Kelly PJA, Green TC, Rich JD, Vento SA, Bailey A, Silva V, et al. Xylazine awareness and suspected presence in the illicit drug supply among people who used stimulants in an overdose hotspot, 2023. Subst Use Misuse. 2026;61(2):217\u201326. https:\/\/doi.org\/10.1080\/10826084.2025.2549501.","journal-title":"Subst Use Misuse"},{"issue":"10","key":"1459_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16101756","volume":"16","author":"M Bazargan","year":"2019","unstructured":"Bazargan M, Smith JL, Robinson P, Uyanne J, Abdulrahoof R, Chuku C, et al. Chronic respiratory disease and health-related quality of life of African American older adults in an economically disadvantaged area of Los Angeles. Int J Environ Res Public Health. 2019;16(10):1756. https:\/\/doi.org\/10.3390\/ijerph16101756.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"1459_CR55","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1164\/rccm.202112-2707OC","volume":"206","author":"AJ Schuyler","year":"2022","unstructured":"Schuyler AJ, Wenzel SE. Historical redlining impacts contemporary environmental and asthma-related outcomes in Black adults. Am J Respir Crit Care Med. 2022;206(7):824\u201337. https:\/\/doi.org\/10.1164\/rccm.202112-2707OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1459_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114696","volume":"294","author":"EK Lee","year":"2022","unstructured":"Lee EK, Donley G, Ciesielski TH, Gill I, Yamoah O, Roche A, et al. Health outcomes in redlined versus non-redlined neighborhoods: a systematic review and meta-analysis. Soc Sci Med. 2022;294:114696. https:\/\/doi.org\/10.1016\/j.socscimed.2021.114696.","journal-title":"Soc Sci Med"},{"issue":"5","key":"1459_CR57","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1513\/AnnalsATS.202409-991RL","volume":"22","author":"SA Mein","year":"2025","unstructured":"Mein SA, Liu M, Marinacci LX, Rice MB, Wadhera RK. Neighborhood exposome and prevalence of asthma and Chronic Obstructive Pulmonary Disease in the United States. Ann Am Thorac Soc. 2025;22(5):797\u2013801. https:\/\/doi.org\/10.1513\/AnnalsATS.202409-991RL.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"1459_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202500041","volume":"358","author":"G Floresta","year":"2025","unstructured":"Floresta G, Granzotto A, Patamia V, Arillotta D, Papanti GD, Guirguis A, et al. Xylazine as an emerging new psychoactive substance; focuses on both 5\u2010HT7 and \u03ba\u2010opioid receptors\u2019 molecular interactions and isosteric replacement. Arch Pharm (Weinheim). 2025;358(3):e2500041. https:\/\/doi.org\/10.1002\/ardp.202500041.","journal-title":"Arch Pharm (Weinheim)"},{"key":"1459_CR59","doi-asserted-by":"publisher","unstructured":"Bedard ML, Murray JG, Huang XP, Nowlan AC, Conley SY, Mott SE, et al. Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to naloxone administration [preprint] [Internet]. Neuroscience; 2023 Sep [cited 2023 Oct 3]. Report. Available from: http:\/\/biorxiv.org\/lookup\/doi\/https:\/\/doi.org\/10.1101\/2023.09.08.556914","DOI":"10.1101\/2023.09.08.556914"},{"issue":"1","key":"1459_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14688","volume":"1508","author":"CM Jones","year":"2022","unstructured":"Jones CM, Houry D, Han B, Baldwin G, Vivolo\u2010Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Ann N Y Acad Sci. 2022;1508(1):3\u201322. https:\/\/doi.org\/10.1111\/nyas.14688.","journal-title":"Ann N Y Acad Sci"},{"key":"1459_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2023.107625","volume":"176","author":"RA Rawson","year":"2023","unstructured":"Rawson RA, Erath TG, Clark HW. The fourth wave of the overdose crisis: examining the prominent role of psychomotor stimulants with and without fentanyl. Prev Med. 2023;176:107625. https:\/\/doi.org\/10.1016\/j.ypmed.2023.107625.","journal-title":"Prev Med"},{"key":"1459_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107592","volume":"204","author":"JC Strickland","year":"2019","unstructured":"Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of \u201ctwin epidemics\u201d: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107592.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1459_CR63","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/10826084.2016.1271432","volume":"52","author":"A Al-Tayyib","year":"2017","unstructured":"Al-Tayyib A, Koester S, Langegger S, Raville L. Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse. 2017;52(8):1051\u20138. https:\/\/doi.org\/10.1080\/10826084.2016.1271432.","journal-title":"Subst Use Misuse"},{"key":"1459_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110985","volume":"252","author":"KD Wagner","year":"2023","unstructured":"Wagner KD, Fiuty P, Page K, Tracy EC, Nocera M, Miller CW, et al. Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services. Drug Alcohol Depend. 2023;252:110985. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.110985.","journal-title":"Drug Alcohol Depend"},{"key":"1459_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103791","volume":"107","author":"A Ivsins","year":"2022","unstructured":"Ivsins A, Fleming T, Barker A, Mansoor M, Thakarar K, Sue K, et al. The practice and embodiment of \u201cgoofballs\u201d: a qualitative study exploring the co-injection of methamphetamines and opioids. Int J Drug Policy. 2022;107:103791. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103791.","journal-title":"Int J Drug Policy"},{"key":"1459_CR66","doi-asserted-by":"publisher","DOI":"10.1177\/29767342241252590","author":"K Dunham","year":"2024","unstructured":"Dunham K, Hill K, Kazal H, Butner JL, Hull I, Sue K, et al. In support of Overdose Prevention Centers: position statement of AMERSA, Inc (Association for Multidisciplinary Education and Research in Substance Use and Addiction). Subst Use &amp; Addict J. 2024. https:\/\/doi.org\/10.1177\/29767342241252590.","journal-title":"Subst Use &amp; Addict J"},{"key":"1459_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104339","volume":"125","author":"S Ledlie","year":"2024","unstructured":"Ledlie S, Garg R, Cheng C, Kolla G, Antoniou T, Bouck Z, et al. Prescribed safer opioid supply: a scoping review of the evidence. Int J Drug Policy. 2024;125:104339. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104339.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1459_CR68","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/08445621251314227","volume":"57","author":"M Haines","year":"2025","unstructured":"Haines M, O\u2019Byrne P. Safer Stimulant Supply: program outcomes. Can J Nurs Res. 2025;57(2):324\u20139. https:\/\/doi.org\/10.1177\/08445621251314227.","journal-title":"Can J Nurs Res"},{"issue":"3","key":"1459_CR69","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001107","volume":"17","author":"JM Streck","year":"2023","unstructured":"Streck JM, Klevens RM, O\u2019Cleirigh C, Batchelder AW. Injection of methamphetamine has increased in Boston, Massachusetts: 5 waves of Centers for Disease Control and Prevention state surveillance data. J Addict Med. 2023;17(3):349\u201352. https:\/\/doi.org\/10.1097\/ADM.0000000000001107.","journal-title":"J Addict Med"},{"key":"1459_CR70","unstructured":"Hoffman J. As Fentanyl Deaths Slow, Meth Comes for Maine [Internet]. 2025. Available from: https:\/\/www.nytimes.com\/2025\/04\/16\/health\/meth-maine-fentanyl.html"},{"issue":"1","key":"1459_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-017-0179-5","volume":"14","author":"L Harper","year":"2017","unstructured":"Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J. 2017;14(1):52. https:\/\/doi.org\/10.1186\/s12954-017-0179-5.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1459_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00590-z","volume":"19","author":"JJ Carroll","year":"2022","unstructured":"Carroll JJ, Mackin S, Schmidt C, McKenzie M, Green TC. The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19. Harm Reduct J. 2022;19(1):9. https:\/\/doi.org\/10.1186\/s12954-022-00590-z.","journal-title":"Harm Reduct J"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01459-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:09:06Z","timestamp":1782169746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01459-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01459-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Access to the opioid-detected fatality data was approved by the Connecticut Office of the Chief Medical Examiner (OCME), and the data collected was part of a study that the Yale University Institutional Review Board deemed exempt from review. This overall research project has been reviewed by and approved by Yale Human Research Protections Program (Protocol #2000036264), in accordance with the Belmont Rule.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}